Explicyte

[OncoSTART @OncoStart]

@OncoStart facilite la rencontre entre entreprises innovantes et les talents du secteur de l’oncologie.
📣 Dernières offres d’emploi @SmartImmune_off @ExpliCyte
☞ https://t.co/0Fo4PKZjkL
🔔 Publiez vos offres d’emploi (oncologie) https://t.co/Xkaf3627lJ

[Explicyte @ExpliCyte]

Check out – It’s our favorite image of January!

When science dives into pointillism…What a masterpiece!

Our fish in the ocean highlighting a Peyer’s patch on a human colon FFPE specimen is revealed using our multiplexed TLS detection panel.

https://t.co/yuVXfci0wM

[Explicyte @ExpliCyte]

A new anti-PD1 resistant mouse sarcoma model, ovarian cancer ascites as a remarkable tool for translational research or our GeoMx platform to support support your spatial transcriptomics programs, check out our best highlights of 2022!

https://t.co/CTxmnCEUJz

Stay connected!

[Explicyte @ExpliCyte]

Check out – It’s our ‘UNSHAVED’ image for Movember!
Beyond the mustache, we at Explicyte are calling for awareness to ‘change the face’ of men’s health - mental health issues and especially cancers.

https://t.co/voD9fVcTTR

#Movember #Cancer #Menshealth #Immunohistofluorescence

[Explicyte @ExpliCyte]

Don’t miss to meet us at the @sitcancer Annual Meeting in Boston next week.
Schedule an in-person meeting with us and plan to take a look at our posters!

https://t.co/iESY7gFrFg

#SITC2022 #cancer #oncology #cancerresearch #SITC22 #immunooncology

[Explicyte @ExpliCyte]

We very much look forward to attending the @sitcancer Annual Meeting in Boston from November 8 to 12, and to showcasing our recent research works through our posters.

https://t.co/xv5heui9Tg

#SITC2022 #cancer #oncology #cancerresearch #SITC22 #immunooncology

[Explicyte @ExpliCyte]

Check out – It’s our favorite image of the month!

What a pretty multiplexed image showing the tumor microenvironment (TME) on a human NSCLC section, highlighting PDL1 positive tumor cells surrounded by macrophages and T cells.

https://t.co/mEX8LKgzur

#Immunohistofluorescence

[Explicyte @ExpliCyte]

Discover our main news for the first half of 2022!

Learn about our partnership with @DOMAINtx, new cutting-edge platforms for biomarker translational research as well as our newest featured publications!

https://t.co/yJ53EFYQ73

#CancerResearch #ImmunoOncology #SummerNews

[Explicyte @ExpliCyte]

Ascites is a pathological peritoneal fluid accumulation most frequently associated with ovarian cancer, thereby creating a quite unique tumor microenvironment in which cancer cells spread.

Learn more: https://t.co/QRi1hnAhBL

#ImmunoOncology #CancerResearch

[Explicyte @ExpliCyte]

Check out - it's our favorite image of the month
Summer beginning, look at a real fireworks🎆! Human cerebral cortex nerve cells lit up on section!

Contact us for your digital pathology projects

https://t.co/42I6a4j0Ww

#Immunohistofluorescence #ImmunoOncology #Brain

[Explicyte @ExpliCyte]

A new collaborative work reported in Annals of Oncology and featured at ASCO 2022!

Our recent collaboration with @BERGONIE33 and @GustaveRoussy is published: Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

https://t.co/2acPgmFKW8

#ImmunoOncology

[Explicyte @ExpliCyte]

Our Digital Spatial Profiling data reported in the Journal for ImmunoTherapy of Cancer!

Our biomarker discovery platform has been brought to the fore in a recent publication resulting from a close collaboration with @BERGONIE33
https://t.co/WTKsqZTglF
#DSP #GeoMx @nanostringtech

[Explicyte @ExpliCyte]

New! Olink proteomics joins the dance of our biomarker discovery capacities

As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery.

https://t.co/pFNtOPizAb

#Proteomics

[Explicyte @ExpliCyte]

Save the date!
We will be attending the @ASCO

Annual Meeting #ASCO2022 in Chicago, from June 3 to 7, 2022.
We are eager to meet you there, discuss your research projects and introduce our service offerings.

https://t.co/i3vF2tfglD

#CancerResearch #Oncology #Cancer

[Explicyte @ExpliCyte]

Spotlight on our in vivo advances : we developed and characterized a novel anti-PD1 resistant sarcoma mouse model!

https://t.co/4O68kgGCO4

#Oncology #ImmunoOncology #CancerResearch #Immunotherapy #InVivoAdvance

[Explicyte @ExpliCyte]

We will be attending the #Meet2win event organized by @MATWIN_Bdx on the 12th and 13th of May in Bordeaux.
We will also participate in the Job Dating sessions organized by @OncoStart and @PhDTalent!

#Oncology #ImmunoOncology #JobDating #JobOffer

[Explicyte @ExpliCyte]

Meet us at the @nanostringtech and @OGConferences event on May 5!

Our CEO Dr. Alban Bessede will discuss at 9:10 BST recent findings about new mechanisms underlying response to cancer immunotherapies.

https://t.co/C6zy3DyDqT

#SpatialBiology #Biomarkers #DrugDiscovery

[Explicyte @ExpliCyte]

Back from the #AACR2022, it was a pleasure to introduce our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.
If you didn't get the chance to see our posters, you can download them!

https://t.co/JhgwPewxUs
#Oncology #Cancerresearch

[Explicyte @ExpliCyte]

We will be attending the @AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there, approach your research projects and introduce our service offerings.

https://t.co/KlJGLaaUc9

#AACR2022 #Cancer #CancerResearch

[Explicyte @ExpliCyte]

Our expertise in multiplexed-immunohistofluorescence (IHF) and ommunohistochemistry (IHC) has been highlited in recent scientific publications of collaborative works with @BERGONIE33

https://t.co/akhvyklLq1

#immunology #oncology #immunotherapy #CancerResearch